Cardiovascular disease is the leading cause of death worldwide. Vascular calcification contributes substantially to the burden of cardiovascular morbidity and mortality. This protocol describes a simple method to quantify vascular smooth muscle cell-mediated calcium precipitation in vitro by fluorescent imaging.
Vascular calcification involves a series of degenerative pathologies, including inflammation, changes to cellular phenotype, cell death, and the absence of calcification inhibitors, that concomitantly lead to a loss of vessel elasticity and function. Vascular calcification is an important contributor to morbidity and mortality in many pathologies, including chronic kidney disease, diabetes mellitus, and atherosclerosis. Current research models to study vascular calcification are limited and are only viable at the late stages of calcification development in vivo. In vitro tools for studying vascular calcification use end-point measurements, increasing the demands on biological material and risking the introduction of variability to research studies. We demonstrate the application of a novel fluorescently labeled probe that binds to in vitro calcification development on human vascular smooth muscle cells and determines the real-time development of in vitro calcification. In this protocol, we describe the application of our newly developed calcification assay, a novel tool in disease modeling that has potential translational applications. We envisage this assay to be relevant in a broader spectrum of mineral deposition research, including applications in bone, cartilage, or dental research.
Vascular calcification (VC) is an independent risk factor for cardiovascular morbidity and mortality1,2,3. Long considered a passive chemical process of ectopic mineral deposition, it now appears a modifiable tissue healing response involving the active contribution of various cells including activated vascular smooth muscle cells (hVSMC) as a driver of the disease4,5. In vivo VC can be measured by multislice CT scans as an assessment of atherosclerotic burden6,7,8. Currently, a paradigm shift is underway, wherein VC severity is becoming recognized as a risk factor in cardiovascular disease, type II diabetes, chronic kidney disease, and ageing9,10,11,12,13,14,15.
hVSMCs are the most abundant cell type in the cardiovascular system and a principal actor in the development of VC. In vitro hVSMC-induced calcification is a widely used disease model to study cardiovascular disease16,17. However, most protocols for the detection of in vitro calcification use end-point measurements that can limit data acquisition, require greater use of cellular material, and can slow research. Common methods for the detection of in vitro hVSMC calcification include the o-cresolphthalein assay, which measures solubilized calcium deposition against total protein and requires cell lysis18. Also, Alizarin Red staining is used, which binds directly to calcium deposits on fixed cells or tissue19. To study hVSMC calcification over time with either o-cresolphthalein or Alizarin Red requires batches of replicates per time point, increasing the demand on biological material, and in turn, increasing the chance of variability.
In this paper, we detail the method for the application of a novel assay that utilizes hVSMCs with a fluorescent imaging probe to determine in vitro VC progression as well as function as a singular end-stage calcification assay. We previously demonstrated that this assay is directly comparable to the o-cresolphthalein and Alizarin Red methods and can be used to distinguish between varying culture conditions20. In addition to real-time measurements, this assay may be used to determine the propensity of serum or plasma samples as a surrogate marker for clinical VC development20. This will aid in the application of biological strategies of cardiovascular sciences and disease modeling. A further application of the assay may be as a translational BioHybrid system to assess VC severity or progression from blood constituents such as serum or plasma.
1. Cell seeding, maintenance, and calcification induction
2. Calcification detection via imaging
NOTE: The following protocol provides the general steps to be taken in preparation, imaging, and data analysis. Screenshots supporting the instructions for each step using an automated imaging platform and corresponding image analysis software (see Table of Materials for details) are provided in Supplemental File 2 and Supplemental File 3. Other imaging instruments and image processing tools may be used to apply this protocol. However, repeated imaging at the same location in each well is crucial for meaningful data acquisition. Creating a protocol to image calcification and re-use at every imaging step is necessary for obtaining reproducible results. The first time applying the method, follow the steps below to prepare before the imaging.
3. Data analysis
NOTE: For detailed screenshots on how to perform the data analysis using an automated imaging platform and corresponding image analysis software (see Table of Materials for details), please see Supplemental File 4. If using alternative imaging instruments or analysis software, the images should be exported and batch processed ensuring that the exposure, fluorescence threshold, or intensity are adjusted equally for all images in a comparative data set.
The outcome includes original images of HOECHST-stained nuclei, RFP-labeled calcification, and brightfield images. Different stages of calcification ranging from low (Figure 2) to high (Figure 3) may be detected and analyzed. Calcification can usually be spotted as black speckles using light microscopy (Figure 2D and Figure 3B, arrows indicate calcification), which are useful for primary assessment and to determine when to start imaging. For improved signal-to-noise ratio, the processed RFP images should be analyzed to quantify calcification (Figure 2F and Figure 3D, arrows indicate calcification). Finally, data may be presented as a bar graph comparing two or more conditions at one time point, accompanied by representative images (Figure 4A,B,C). Data should be displayed normalized to cell count (e.g., as calcification area per cell). Data may also be displayed as time-series data showing the same condition at various time points (Figure 4D).
Figure 1: Visual abstract summarizing the steps for the semi-automated calcification detection and analysis. Please click here to view a larger version of this figure.
Figure 2: Example of early-stage calcification. (A)The overlay image can be displayed and analyzed as (B) separate DAPI (nuclei), (C) RFP (calcification), and (D) brightfield images. (E) Nuclei are identified by the software and can be highlighted as yellow circles to adjust the settings. (F) For analysis of the RFP signal, images are pre-processed to reduce background signal and, (G) subsequently, a threshold can be set to measure the signal. Arrows indicate calcification in the (D) brightfield and (F & G) transformed RFP images. Please click here to view a larger version of this figure.
Figure 3: Example of later-stage calcification. (A) The overlay image can be displayed and analyzed as separate (B) brightfield, (C) RFP (calcification), and (E) DAPI (nuclei) images. (D) For analysis of the RFP signal, images are pre-processed to reduce background signal. Arrows indicate calcification in the (B) brightfield and (D) transformed RFP images. Please click here to view a larger version of this figure.
Figure 4: Representative comparison between low and high calcification of hVSMC after 14 days in culture with calcification medium. Commonly, data may be displayed as a bar graph and analyzed employing the unpaired Student's t-test. Representative images of (A) low calcification and (B) high calcification. The red signal (RFP) reflects calcification, and the blue signal (HOECHST) displays nuclei. (C) Calcification presented as fetuin A-RFP positive signal (total area) per cell. (D) Example of a calcification assay measured over time. Please click here to view a larger version of this figure.
Supplemental Figure 1: Example of a range of wells used for a calcification experiment with hVSMCs. The outer ring of the wells is not used for the calcification experiment but filled with liquid. Please click here to download this File.
Supplemental File 1: Notes on the cell culture and maintenance of hVMSC. Please click here to download this File.
Supplemental File 2: Automated imaging protocol. Please click here to download this File.
Supplemental File 3: Image analysis protocol. Please click here to download this File.
Supplemental File 4: Data analysis protocol. Please click here to download this File.
In this manuscript, we describe a semi-automated method for in vitro calcification determination. For this method, three critical steps of hVSMC calcification should be optimized. First, cellular density is critical for hVSMC calcification development. Low densities of hVSMCs will result in slow or no calcification and cell death due to the lack of cell-to-cell contact and the stress that is induced under calcifying conditions21. High cellular densities result in over-confluency, after which cells become senescent22 and calcification development stops. It is critical to seed roughly 70% confluency in the well plate that will be used for subsequent calcification development, ensuring proliferative capacity and cellular connections of hVSMCs.
Secondly, the cell culture media that will be used for calcification induction requires optimization. Within vascular calcification research, a variety of conditions and media compositions have been reported to calcify hVSMCs23,24. We believe the method is suitable to detect all kinds of in vitro-mediated calcification, and it has been used to detect calcium, phosphate, or calcium-phosphate stimulated deposits. Regardless of the mode for calcification induction, optimization of the calcifying media is pivotal. In the presented protocol, we optimized calcification induction by using M199 with a total calcium concentration of 4.5 mM Ca2+ with 2.5% FBS.
Lastly, local differences in plates during calcification have been observed. It is critical to apply random loading of technical replicates to prevent sample bias. Additionally, loading of the outer well lanes should be avoided as these wells always calcify more rapidly in the 48-well setting. This is potentially caused by the dysregulation of intraplate humidity, wherein not using the outermost wells and loading these wells with large volumes of liquid helps control for this.
While the calcification assay itself can require multiple optimization steps to ensure reproducibility with a particular setup, once up and running this becomes straightforward. Calcification assays can be run simultaneously and repeatedly under established conditions without the need for further optimization. hVSMC-mediated calcification can be challenging and require experimentation before the robustness of assays has been achieved. A researcher should be able to determine the optimal timing before starting regular imaging, which can take up to 1 week. A fixed imaging schedule can be established from the start of the experiment, although this may produce many images without differential read-outs, use a relatively large amount of data storage for images, and be time-consuming in analysis.
The procedure described in this protocol is one way to perform the analysis of the calcification assay. For other purposes, the procedure should be adjusted accordingly. Our analysis using the referenced automated imaging platform ensures reproducibility, although analysis can be performed using any live cell and temperature- and CO2-controlled imaging device. Additionally, the corresponding commercial software packages are optimized for high content cellular screening and analysis, ideally suited to measuring calcification propensity over time. Other software solutions, such as the freeware ImageJ, can provide image analysis and quantify calcification development as well.
The imaging of late-stage calcification plates can be difficult due to issues with autofocusing should the culture encounter floating debris, resulting in a reduced number of sharp images and replicates. Image analysis should be adjusted accordingly, and some solutions have been developed in the software employed in this protocol to improve and simplify analysis.
Cellular heterogeneity plays a crucial role in the quantification of calcification in vitro. In this platform, we use hVSMCs as biosensors for the development of calcification. Primary hVSMCs are derived from various donors with different underlying vascular pathologies; therefore, this assay is still subject to high variability due to the heterogeneity of VSMCs batches. A possible solution is the use of immortalized cell lines or the use of hVSMCs derived from pluripotent stem cells.
Another limitation is that the quantification method is still sensitive to subjectivity. Subjectivity in calcification assays arises because of end-point assays, which were only available until recently. Researchers must decide when to stop the experiment and measure calcification, increasing the subjectivity of the assay. We believe the method introduced in this manuscript is superior as we measure over time and can compare calcification development in a certain period. Linked to this, the illumination setting needs to be adjusted for every time point separately due to the decrease in signal over time. Due to this, the amount of signal represented in a picture is still swayed by an individual's opinion. It is crucial that illumination is performed with the highest signal-to-noise ratios so that post-image analysis can be performed as objectively as possible.
Although we see the subjectivity of this assay as a limitation, we believe that it is superior to other in vitro calcification methods. Unlike the existing methods, our semi-automated calcification assay has the advantage that images can be analyzed anonymously, thereby providing an independent blinded opinion. Additionally, the images can be analyzed at a later stage with the same defined settings across a data set, thereby reducing subjectivity.
The current methods of calcification determination rely on end-point measurements or lack the vascular component25,26,27. Within the clinic, tools such as computed tomography, intravascular ultrasound, and magnetic resonance imaging are expensive and a burden for patients. Biomarker research has proven its use but does not reflect the calcification burden of patients. We believe that this semi-automated assay uses not only one single biomarker but a collection of circulating components, reflecting a patient's cardiovascular status. This can be used to measure a calcification response as a biosensor. Potential further applications of the described method include patients' serum screening for in vitro calcification development as a surrogate marker for personalized development of vascular calcification. The platform has demonstrated its sensitivity toward dialysis and vitamin K treatment, in addition to both metabolic and non-metabolic diseases that are linked to patients with poor cardiovascular status and prognosis20. Since the assay's principle is based on the detection of calcium crystals, we hypothesize that it might also be relevant in other research areas where mineralization may be of relevance, such as osteoarthritis, osteoporosis, bone regenerative medicine, or dental research.
The authors have nothing to disclose.
This research was funded by the European Union's Horizon 2020 research and innovation programs under the Marie Sklodowska-Curie grant agreement No 722609 and 764474, NWO ZonMw (MKMD 40-42600-98-13007). This research was supported by BioSPX. WJ-D received funding from the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) TRR219-project ID 322900939 and project ID 403041552
Calcium chloride, 93%, anhydrous | Thermo Fisher Scientific | 349615000 | |
Costar 6-well Clear TC-treated well plates | Corning | 3516 | |
Cytation 3 System | BioTek, Abcoude, The Netherlands | ||
Fetal Bovine Serum | Merck | F7524-100ML | |
Fetuin-A-Alexa Fluor-546 | Prepared in-house | ||
Gen5 Software v3.10 | BioTek | ||
Gibco Medium 199 | Thermo Fisher Scientific | 11150059 | |
Hoechst 33342, Trihydrochloride | Thermo Fisher Scientific | H3570 | |
PBS (10X), pH 7.4 | Thermo Fisher Scientific | 70011044 | |
Penicillin-Streptomycin | Thermo Fisher Scientific | 15140122 | |
Trypsin-EDTA (0.05%), phenol red | Thermo Fisher Scientific | 25300062 |